Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress
Arcturus reported Q1 revenue of $2.06 million, a $27.3 million decrease from the prior year driven by the conclusion of infectious disease vaccine collaborations, while the net loss widened to $27.0 million or ($0.95) per share. Despite the financial headwinds, the company strengthened its balance sheet with $213.4 million in cash, securing a runway extending beyond the second quarter of 2028.
Key figures
- Revenue
- 2061000
- Revenue Yoy
- $27.3 million decrease
- Net loss
- 27000000
- Ga expenses
- 9500000
- Rd expenses
- 21500000
- Cash position
- 213400000
- Operating expenses
- 31000000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.